Cash acquired in connection with purchase of non-controlling interest

This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementCash Flow Statement

SectionFinancing

CategoryCapital Allocation

SignalHigher is better

VolatilityVolatile

First reportedQ1 2021

Last reportedQ4 2025

An increase indicates the acquisition of entities with existing cash reserves.

Cash balances obtained as part of the acquisition of a non-controlling interest in another entity. This represents the l...

Relevant for companies frequently engaging in M&A or consolidation of minority interests.

Metric ID: financing_cash_acquired_in_connection_with_purchase_of_n_4a95e4

5 years

	FY'21	FY'22	FY'23	FY'24	FY'25
Value	$0.00	$0.00	$4.97M	$0.00	$0.00
YoY Change	—	—	—	-100.0%	—

Range$0.00 – $4.97M

Avg YoY Growth-100.0%

Median YoY Growth-100.0%

What is Royalty Pharma's cash acquired in connection with purchase of non-controlling interest?: Royalty Pharma (RPRX) reported cash acquired in connection with purchase of non-controlling interest of $0.00 in Q4 2025.
What does cash acquired in connection with purchase of non-controlling interest mean?: Cash received when buying out a minority interest in another company.